A Dose Escalation Study of Bradanicline in Refractory Chronic Cough

This study will have two 21-day treatment periods separated by a 14-day washout period. There
will be a 14-day follow-up period.

Inclusion Criteria:

- Chest radiograph or computed tomography (CT) scan of the thorax within the last 1 year
not demonstrating any abnormality considered to be significantly contributing to the
refractory chronic cough

- Diagnosis of refractory chronic cough or unexplained cough for at least one year

- Women of child-bearing potential who use 2 forms of acceptable birth control method

- Male subjects and their partners of child-bearing potential who use 2 methods of
acceptable birth control

- Has provided written informed consent

Exclusion Criteria:

- Current smoker (cigarettes or e-cigarettes) or has given up smoking within the past 12
months

- Currently taking an ACE-inhibitor or requiring treatment with an ACE-inhibitor during
the study or within 12 weeks prior to the Baseline Visit

- Has an upper or lower respiratory tract infection or recent significant change in
pulmonary status within 4 weeks of the Baseline Visit

- Has a history of cystic fibrosis

- Has a history of malignancy within 5 years prior to the Baseline Visit

- Has active hepatitis infection

- Has a history of human immunodeficiency virus (HIV) infection

- Has a positive test for any drug of abuse

- Has a history of hypersensitivity to bradanicline or any of its components